Cancer - Riboscience, LLC

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05270213

A First-In-Human, Phase 1 a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Unresectable, Recurrent or Metastatic Tumors

Drug

RBS2418

Condition

Advanced Unresectable, Recurrent or Metastatic Tumors